Article

Oncologist Lewis Silverman on Revlimid for Patients with Myelodysplastic Syndrome

Lewis Silverman, an oncologist with Mount Sinai Medical Center, discusses a clinical trial involving Revlimid (lenalidomide) for patients with a type of myelodysplastic syndrome.

Lewis Silverman, an oncologist with Mount Sinai Medical Center, discusses a clinical trial involving Revlimid (lenalidomide) for patients with a type of myelodysplastic syndrome.

Revlimid is currently approved for patients with a specific type of MDS that contains a chromosomal abnormality called deletion 5q.

The phase 3 trial,which was reported at the 2014 American Society of Hematology, includes patients with MDS who do not have the chromosomal abnormality but have low-risk disease.

The purpose of the study was to find out if Revlimid could reduce the number of red blood cell transfusions needed by anemic (transfusion-dependent) patients with low- or intermediate-risk MDS without a deletion 5q chromosome abnormality.

Silverman says the study confirms that about a quarter of patients who do not have the deletion 5q abnormality can become transfusion independent, and the duration of treatment response is about eight or nine months.

Related Videos
Dr. Alan Tan is a genitourinary oncology (GU) and melanoma specialist at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee; an associate professor of medicine in the Division of Hematology and Oncology at Vanderbilt University Medical Center; and GU Executive Officer with the Alliance for Clinical Trials in Oncology.
Dr. Chandler Park, a medical oncologist of Genitourinary Medical Oncology, at the Norton Healthcare Institute, in Louisville, Kentucky.
Image of woman with blonde hair.
Image of woman with blonde hair.
Image of woman with brown hair.
Image of woman.
Dr. Andreas M. Kaiser is a professor and chief of the Division of Colorectal Surgery in the Department of Surgery at City of Hope comprehensive cancer center in Duarte, California.
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.